Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Abraxane,ABX1001,2022,USA,MDV,350,62,98,2,27.5,18,85,2,15,40,30,15,55,25,15,5,20,45,30,12,3,2,5,4,35,60,45,AC,Taxol,TC,CMF,25,35,30,40,70,55,20,50,30,60,1.5
Abraxane,ABX1002,2023,Canada,Claim Database,420,68,97,3,28.1,22,78,1,18,38,32,12,52,28,14,6,22,42,31,15,4,3,6,5,38,62,48,AC-T,FEC,Docetaxel,AC,28,32,33,42,72,57,18,52,30,62,1.7
Abraxane,ABX1003,2023,UK,MDV,280,65,96,4,26.8,25,80,3,12,42,28,18,58,22,16,4,18,48,26,10,2,1,4,3,32,58,42,EC,CMF,FEC-D,Taxol,22,38,28,38,68,52,22,48,30,58,1.3
